Symbiotec Pharmalab IPO
Symbiotec Pharmalab IPO is a mainboard IPO raising ₹1,757 Cr at ₹938 – ₹988 a share. It listed on 1 Sept 2026 at ₹988, 0.0% against its issue price of ₹988, and trades at ₹1,139 today (+15.3% since issue). It was subscribed 71× in total.
71.3 times more demand than shares on offer
populated partly populated we hold nothing here — the tab says why
What this company actually does
Read out of the prospectus’s business section, stripped of its marketing language.
Symbiotec Pharmalab Limited is a research-driven pharmaceutical and biotechnology company that manufactures corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs) using fermentation and multi-step chemical synthesis. It operates across three platforms — organic chemistry, biotechnology, and complex injectables (double-chamber vials, bags and syringes) — and runs a vertically integrated 'farm/microbe-to-pharmacy' model serving generic and specialty pharmaceutical companies in over 40 countries. Its facilities are located in Madhya Pradesh, India (Rau, Pithampur, Ujjain and Mhow).
How it earns
Primarily by selling its own corticosteroid and steroidal-hormone APIs globally, with smaller contributions from newly launched CDMO services and a complex injectables business.
Who buys
Over 200 customers in more than 40 countries, comprising over 50 domestic and over 150 export customers (key generic and specialty pharmaceutical firms in the US, Europe and Asia). Top 5 customers contributed 43.01% of revenue from sale of products in Fiscal 2026; top 10 customers contributed 57.59%. Two of the top five customers are innovator companies, each with relationships exceeding 10 years and supplied with 4 products each in Fiscal 2026. Specific customer names are not disclosed in the prospectus text.
Scale
As of March 31, 2026: 4 manufacturing facilities in Madhya Pradesh (Rau, Pithampur, Ujjain, Mhow) with aggregate maximum chemical synthesis capacity of 584.67 MT, fermentation capacity of 700 KL, and complex injectables capacity of 20 million vials per annum; 156 R&D scientists/engineers across 3 dedicated R&D centres in Indore; over 2,500 employees; fermentation bioreactors spanning 5 KL, 35 KL and 100 KL scales (with a proposed additional 14 KL biologics capacity under construction).
What it says sets it apart
- Global volume market share of 38.2% in corticosteroid APIs and 23.8% in steroidal-hormone APIs in Fiscal 2026 (per F&S Report), with volume share leadership in Hydrocortisone (80.1%), Testosterone (76.4%) and Methylprednisolone (76.0%).
- Only Indian and global company with presence across the top 10 corticosteroid and steroidal-hormone APIs in Fiscal 2026, across a portfolio of over 60 APIs.
- Backward-integrated 'farm/microbe-to-pharmacy' platform with in-house fermentation-based production of KSMs/precursors for over 80% of products by revenue, with chemistry capability for APIs with up to 400 synthesis steps under cGMP.
- 43 US FDA Drug Master Filings and 23 EDQM Certificates of Suitability (CEPs), with no critical observations in 108+ customer and 9+ regulatory inspections over the last three Fiscals; one of the first generics companies globally to develop double-chamber vials through backward integration for Methylprednisolone Sodium Succinate and Hydrocortisone Sodium Succinate injections.
- Among the few companies globally to have developed a conjugated equine estrogen API (Premarin generic) covering 82 US FDA-mandated components, under a collaboration with a global specialty pharma partner generating multi-million dollar revenues including milestone payments and profit-sharing.
Revenue mix
The numbers at a glance
The price they’re asking →derived: cut-off price Rs988 / stated EPS Rs19 (FY2026 (year ended March 31, 2026) diluted EPS, restated consolidated, per Ind AS 33). Stated figures are as printed in the prospectus; margins, growth and the borrowing ratio are computed from its own summary table. A multiple is one lens, not a verdict.
Where the money goes
The offer →92% of this issue is existing shareholders cashing out — only the fresh issue reaches the business.
How its cohort has done
63 mainboard issues listed in 2026 that we can price today. This is the group this issue belongs to.
Neither figure is a forecast for this issue — they describe what happened to comparable issues. Full cohort analytics →
How the book finished
The category split is the number worth reading, not the total.
QIB: 172× their allocation. Retail: 13×.
What we hold for this issue
Stated up front on every issue, so a sparse page reads as a fact about the source rather than a broken one.
Led by JM Financial Limited — median +29.1% across the 102 of its issues we can price. All lead managers →
What happens when
Next: the UPI mandate expires on 8 Oct 2026.
What to watch
- 92% of the issue is offer for sale — only ₹150 Cr of new money reaches the company.
- Priced at 52× earnings — 43% below the median of the peers the issuer itself names.
- Its cohort's record: median +33.9% since issue price, 27% now below it — a base rate, not a forecast.
Each line restates a disclosure from the prospectus or the exchanges — nothing here is a recommendation to apply to this issue.
Track SYMBIOTEC PHARMALAB LTD
Results, orders, board decisions and every other filing — summarised and sent to your WhatsApp the minute they are out.
Figures are as published by the exchanges and the issuer’s prospectus. MarketPing publishes facts, comparisons and history only — nothing here is a recommendation to apply to this issue, and we do not publish grey market premium.